Modulation of protein-protein interactions by stabilizing/mimicking protein secondary structure elements.

In view of the crucial role of protein-protein intercommunication both in biological and pathological processes, the search of modulators of protein-protein interactions (PPIs) is currently a challenging issue. The development of rational strategies to imitate key secondary structure elements of protein interfaces is complementary to other approaches based on the screening of synthetic or virtual libraries. In this sense, the present review provides representative examples of compounds that are able to disturb PPIs of therapeutic relevance, through the stabilization or the imitation of peptide hot-spots detected in contact areas of the interacting proteins. The review is divided into three sections, covering mimetics of the three main secondary structural elements found in proteins, in general, and in protein-protein interfaces, in particular (alpha-helices, beta-sheets, and reverse turns). Once the secondary element has been identified, the first approach typically involves the translation of the primary peptide structure into different cyclic analogues. This is normally followed by gradual decrease of the peptide nature through combination of peptide and non-peptide fragments in the same molecule. The final step usually consists in the development of pertinent organic scaffolds for appending key functional groups in the right spatial disposition, as a means towards totally non-peptide small molecule PPI modulators.

[1]  D. Selkoe,et al.  Alzheimer's Disease--Genotypes, Phenotype, and Treatments , 1997, Science.

[2]  L. Vassilev,et al.  Targeting protein–protein interactions for cancer therapy , 2005, Journal of Molecular Medicine.

[3]  K. Gehring,et al.  Solution Structure and Internal Motion of a Bioactive Peptide Derived from Nerve Growth Factor* , 1998, The Journal of Biological Chemistry.

[4]  T. Barrette,et al.  Probabilistic model of the human protein-protein interaction network , 2005, Nature Biotechnology.

[5]  Dajun Yang,et al.  Macrocyclization in the design of non-phosphorus-containing Grb2 SH2 domain-binding ligands. , 2004, Journal of medicinal chemistry.

[6]  K. Burgess,et al.  New templates for syntheses of ring-fused, C(10) beta-turn peptidomimetics leading to the first reported small-molecule mimic of neurotrophin-3. , 2002, Journal of medicinal chemistry.

[7]  M. Schwaiger,et al.  Carbohydrate Derivatives for Use in Drug Design: Cyclicαv-Selective RGD Peptides , 2000 .

[8]  Bernhard Pfeiffer,et al.  Over One Hundred Peptide‐Activated G Protein‐Coupled Receptors Recognize Ligands with Turn Structure , 2005 .

[9]  Yong Wang,et al.  Helix-stabilized cyclic peptides as selective inhibitors of steroid receptor–coactivator interactions , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[10]  R. Liskamp Conformationally Restricted Amino Acids and Dipeptides, (non) Peptidomimetics and Secondary Structure Mimetics , 1994 .

[11]  J. Urban,et al.  Sculpted immunogens; B-cell epitope optimization using constrained secondary structure libraries. , 1996, Bioorganic & medicinal chemistry.

[12]  Shaomeng Wang,et al.  Structure-based design, synthesis, and evaluation of conformationally constrained mimetics of the second mitochondria-derived activator of caspase that target the X-linked inhibitor of apoptosis protein/caspase-9 interaction site. , 2004, Journal of Medicinal Chemistry.

[13]  Michael G. C. Kahn Peptide Secondary Structure Mimetics: Recent Advances and Future Challenges , 1993 .

[14]  D. Potenza,et al.  Targeting integrins: insights into structure and activity of cyclic RGD pentapeptide mimics containing azabicycloalkane amino acids. , 2006, Bioorganic & medicinal chemistry.

[15]  Joshua A. Kritzer,et al.  Solution Structure of a β-Peptide Ligand for hDM2 , 2005 .

[16]  Shibo Jiang,et al.  Design of a protein surface antagonist based on alpha-helix mimicry: inhibition of gp41 assembly and viral fusion. , 2002, Angewandte Chemie.

[17]  D. Selkoe Alzheimer's disease: genotypes, phenotypes, and treatments. , 1997, Science.

[18]  Wei Yang,et al.  Small molecule integrin antagonists that bind to the beta2 subunit I-like domain and activate signals in one direction and block them in the other. , 2003, Immunity.

[19]  Y. Pommier,et al.  Interfacial inhibition of macromolecular interactions: nature's paradigm for drug discovery. , 2005, Trends in pharmacological sciences.

[20]  G. Verdine,et al.  An All-Hydrocarbon Cross-Linking System for Enhancing the Helicity and Metabolic Stability of Peptides , 2000 .

[21]  Horst Kessler,et al.  N-methylated cyclic RGD peptides as highly active and selective αvβ3 integrin antagonists , 1999 .

[22]  Gabriel Lopez-Berestein,et al.  Growth inhibition of breast cancer cells by Grb2 downregulation is correlated with inactivation of mitogen-activated protein kinase in EGFR, but not in ErbB2, cells , 1999, Oncogene.

[23]  T Ueda,et al.  A novel anti-HIV synthetic peptide, T-22 ([Tyr5,12,Lys7]-polyphemusin II). , 1992, Biochemical and biophysical research communications.

[24]  Jean Chmielewski,et al.  Inhibiting protein-protein interactions using designed molecules. , 2005, Current opinion in structural biology.

[25]  Dajun Yang,et al.  A novel macrocyclic tetrapeptide mimetic that exhibits low-picomolar Grb2 SH2 domain-binding affinity. , 2003, Biochemical and biophysical research communications.

[26]  Robert J Fisher,et al.  Examination of phosphoryl-mimicking functionalities within a macrocyclic Grb2 SH2 domain-binding platform. , 2005, Journal of medicinal chemistry.

[27]  D. Whitcomb Acute pancreatitis: Molecular biology update , 2003, Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract.

[28]  Arun K. Ghosh,et al.  Structure-based design: synthesis and biological evaluation of a series of novel cycloamide-derived HIV-1 protease inhibitors. , 2005, Journal of medicinal chemistry.

[29]  B. Gibbs,et al.  Small Peptide Mimics of Nerve Growth Factor Bind TrkA Receptors and Affect Biological Responses (*) , 1995, The Journal of Biological Chemistry.

[30]  A. Cuello,et al.  A designed peptidomimetic agonistic ligand of TrkA nerve growth factor receptors. , 2000, Molecular pharmacology.

[31]  Edgar Jacoby,et al.  Biphenyls as potential mimetics of protein α-helix , 2002 .

[32]  C. E. Peishoff,et al.  Potent, selective, orally active 3-oxo-1,4-benzodiazepine GPIIb/IIIa integrin antagonists. , 1996, Journal of medicinal chemistry.

[33]  A. Levine,et al.  Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain , 1996, Science.

[34]  Razvan C. Bunescu,et al.  Consolidating the set of known human protein-protein interactions in preparation for large-scale mapping of the human interactome , 2005, Genome Biology.

[35]  John A. Robinson,et al.  A virosome-mimotope approach to synthetic vaccine design and optimization: synthesis, conformation, and immune recognition of a potential malaria-vaccine candidate. , 2003, Angewandte Chemie.

[36]  T. Fan,et al.  Caspase family proteases and apoptosis. , 2005, Acta biochimica et biophysica Sinica.

[37]  M. Manthorpe,et al.  Synthetic NGF peptide derivatives prevent neuronal death via a p75 receptor‐dependent mechanism , 1997, Journal of neuroscience research.

[38]  P. Alewood,et al.  Conformational constraints: nonpeptide beta-turn mimics. , 1990, Journal of Molecular Recognition.

[39]  P. Roller,et al.  Global optimization of conformational constraint on non-phosphorylated cyclic peptide antagonists of the Grb2-SH2 domain. , 2003, Bioorganic & medicinal chemistry.

[40]  Joshua A. Kritzer,et al.  β-Peptides as inhibitors of protein–protein interactions , 2005 .

[41]  K. Mayo,et al.  Designed beta-sheet-forming peptide 33mers with potent human bactericidal/permeability increasing protein-like bactericidal and endotoxin neutralizing activities. , 1998, Biochimica et biophysica acta.

[42]  Do-Hyoung Kim,et al.  Proteomimetic libraries: design, synthesis, and evaluation of p53-MDM2 interaction inhibitors. , 2006, Journal of combinatorial chemistry.

[43]  J. Nicholas,et al.  Small molecule antagonists of proteins. , 2003, Biochemical pharmacology.

[44]  D. Fairlie,et al.  Proteases universally recognize beta strands in their active sites. , 2005, Chemical reviews.

[45]  John A. Robinson,et al.  A New Family of β‐Hairpin Mimetics Based on a Trypsin Inhibitor from Sunflower Seeds , 2002, Chembiochem : a European journal of chemical biology.

[46]  T. Springer,et al.  A dimeric crystal structure for the N-terminal two domains of intercellular adhesion molecule-1. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[47]  D. Fairlie,et al.  Beta-strand mimicking macrocyclic amino acids: templates for protease inhibitors with antiviral activity. , 2002, Journal of medicinal chemistry.

[48]  H. Willems,et al.  The design of dipeptide helical mimetics: the synthesis, tachykinin receptor affinity and conformational analysis of 1,1,6-trisubstituted indanes. , 1996, Bioorganic & medicinal chemistry.

[49]  J. Osbourn,et al.  Human antibodies by design , 1998, Nature Biotechnology.

[50]  Shaomeng Wang,et al.  Structure-based design of potent, conformationally constrained Smac mimetics. , 2004, Journal of the American Chemical Society.

[51]  Shaomeng Wang,et al.  Chimeric (α/β + α)-Peptide Ligands for the BH3-Recognition Cleft of Bcl-xL: Critical Role of the Molecular Scaffold in Protein Surface Recognition , 2005 .

[52]  Antagonists of the Src homology 2 (SH2) domains of Grb2, Src, Lck and ZAP-70. , 2001, Current medicinal chemistry.

[53]  C. E. Peishoff,et al.  Design and synthesis of a C7 mimetic for the predicted gamma-turn conformation found in several constrained RGD antagonists. , 1992, Journal of medicinal chemistry.

[54]  M. García-López,et al.  2(S)-amino-3-oxo-11b(R)-hexahydroindolizino[8,7-b]indole-5(S)-carboxylate as a new type of β-turn dipeptide mimetic , 1994 .

[55]  D. Kohda,et al.  A comparative study of the solution structures of tachyplesin I and a novel anti-HIV synthetic peptide, T22 ([Tyr5,12, Lys7]-polyphemusin II), determined by nuclear magnetic resonance. , 1993, Biochimica et biophysica acta.

[56]  V. Madison,et al.  Synthesis and biological activity of macrocyclic inhibitors of hepatitis C virus (HCV) NS3 protease. , 2005, Bioorganic & medicinal chemistry letters.

[57]  T. Tomaszek,et al.  A novel constrained reduced-amide inhibitor of HIV-1 protease derived from the sequential incorporation of gamma-turn mimetics into a model substrate. , 1993, Journal of medicinal chemistry.

[58]  H. Kim,et al.  A Merger of Rational Drug Design and Combinatorial Chemistry: Development and Application of Peptide Secondary Structure Mimetics , 2001 .

[59]  R. Nussinov,et al.  Protein–protein interactions: Structurally conserved residues distinguish between binding sites and exposed protein surfaces , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[60]  Selective formation of homo- and heterobivalent peptidomimetics. , 2003, Journal of medicinal chemistry.

[61]  Dajun Yang,et al.  Synthesis of a C-terminally biotinylated macrocyclic peptide mimetic exhibiting high Grb2 SH2 domain-binding affinity. , 2005, Bioorganic & medicinal chemistry.

[62]  Joshua A. Kritzer,et al.  Helical β-Peptide Inhibitors of the p53-hDM2 Interaction , 2004 .

[63]  Youmei Xie,et al.  Nerve Growth Factor (NGF) Loop 4 Dimeric Mimetics Activate ERK and AKT and Promote NGF-like Neurotrophic Effects* , 2000, The Journal of Biological Chemistry.

[64]  Baoguang Zhao,et al.  Structure activity relationships of 5-, 6-, and 7-methyl-substituted azepan-3-one cathepsin K inhibitors. , 2006, Journal of medicinal chemistry.

[65]  Ulrich Hommel,et al.  Small Molecule Inhibitors Induce Conformational Changes in the I Domain and the I-like Domain of Lymphocyte Function-associated Antigen-1 , 2002, The Journal of Biological Chemistry.

[66]  H. Hauser,et al.  β‐Peptides as Inhibitors of Small‐Intestinal Cholesterol and Fat Absorption , 1999 .

[67]  John A. Robinson,et al.  Properties and structure-activity studies of cyclic beta-hairpin peptidomimetics based on the cationic antimicrobial peptide protegrin I. , 2005, Bioorganic & medicinal chemistry.

[68]  K. Burgess,et al.  Molecular basis of neurotrophin-receptor interactions. , 2003, Journal of medicinal chemistry.

[69]  D. Mochly‐Rosen,et al.  Peptide modulators of protein–protein interactions in intracellular signaling , 1998, Nature Biotechnology.

[70]  K. Satyshur,et al.  Novel Cyclic Biphenyl Ether Peptide β-Strand Mimetics and HIV-Protease Inhibitors , 1997 .

[71]  L. Presta,et al.  Generation of an LFA-1 antagonist by the transfer of the ICAM-1 immunoregulatory epitope to a small molecule. , 2002, Science.

[72]  P. Darke,et al.  Design and synthesis of peptidomimetic inhibitors of HIV-1 protease and renin. Evidence for improved transport. , 1994, Journal of medicinal chemistry.

[73]  John A. Robinson,et al.  Structural mimicry of retroviral tat proteins by constrained beta-hairpin peptidomimetics: ligands with high affinity and selectivity for viral TAR RNA regulatory elements. , 2004, Journal of the American Chemical Society.

[74]  J. Clemente,et al.  Synthesis of malarial plasmepsin inhibitors and prediction of binding modes by molecular dynamics simulations. , 2005, Journal of medicinal chemistry.

[75]  H. Kessler,et al.  Conformational Analysis of a Cyclic RGD Peptide Containing a .psi.[CH2-NH] Bond: A Positional Shift in Backbone Structure Caused by a Single Dipeptide Mimetic , 1994 .

[76]  Oliver Zerbe,et al.  Using a β‐Hairpin To Mimic an α‐Helix: Cyclic Peptidomimetic Inhibitors of the p53–HDM2 Protein–Protein Interaction , 2004 .

[77]  A. Hamilton,et al.  Diphenylindane-based proteomimetics reproduce the projection of the i, i+3, i+4, and i+7 residues on an alpha-helix. , 2006, Organic letters.

[78]  Giorgio Palù,et al.  Protein–protein interactions as targets for antiviral chemotherapy , 2002, Reviews in medical virology.

[79]  X Zhang,et al.  A low-molecular-weight inhibitor against the chemokine receptor CXCR4: a strong anti-HIV peptide T140. , 1998, Biochemical and biophysical research communications.

[80]  G. McGaughey,et al.  HIV-1 vaccine development: constrained peptide immunogens show improved binding to the anti-HIV-1 gp41 MAb. , 2003, Biochemistry.

[81]  K. Abromeit Music Received , 2023, Notes.

[82]  D. Weiner,et al.  Design and synthesis of a CD4 beta-turn mimetic that inhibits human immunodeficiency virus envelope glycoprotein gp120 binding and infection of human lymphocytes. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[83]  H. Lehrach,et al.  A Human Protein-Protein Interaction Network: A Resource for Annotating the Proteome , 2005, Cell.

[84]  K. Burgess,et al.  Dimeric β-turn peptidomimetics as ligands for the neurotrophin receptor TrkC , 2001 .

[85]  D. Erdmann,et al.  Structural basis for specificity of GRB2-SH2 revealed by a novel ligand binding mode , 1996, Nature Structural Biology.

[86]  Paramjit S. Arora,et al.  A highly stable short α-helix constrained by a main-chain hydrogen-bond surrogate , 2004 .

[87]  A. D. de Vos,et al.  Nerve growth factor: structure and function , 2001, Cellular and Molecular Life Sciences CMLS.

[88]  D. Krag,et al.  Nonphosphorylated Peptide Ligands for the Grb2 Src Homology 2 Domain* , 1997, The Journal of Biological Chemistry.

[89]  D. Fairlie,et al.  Macrocycles mimic the extended peptide conformation recognized by aspartic, serine, cysteine and metallo proteases. , 2001, Current medicinal chemistry.

[90]  W. V. van Gunsteren,et al.  Dynamical studies of peptide motifs in the Plasmodium falciparum circumsporozoite surface protein by restrained and unrestrained MD simulations. , 1997, Journal of molecular biology.

[91]  Terry Walsh,et al.  Countering cooperative effects in protease inhibitors using constrained beta-strand-mimicking templates in focused combinatorial libraries. , 2004, Journal of medicinal chemistry.

[92]  Z. Yao,et al.  Inhibition of angiogenesis by growth factor receptor bound protein 2-Src homology 2 domain bound antagonists. , 2004, Molecular cancer therapeutics.

[93]  H. Kessler,et al.  Synthesis and Structure−Activity Relationship of Mannose-Based Peptidomimetics Selectively Blocking Integrin α4β7 Binding to Mucosal Addressin Cell Adhesion Molecule-1 , 2003 .

[94]  S. Sebti,et al.  Terephthalamide derivatives as mimetics of helical peptides: disruption of the Bcl-x(L)/Bak interaction. , 2005, Journal of the American Chemical Society.

[95]  John W. Bean,et al.  Direct design of a potent non-peptide fibrinogen receptor antagonist based on the structure and conformation of a highly constrained cyclic RGD peptide , 1993 .

[96]  Alexander D. MacKerell,et al.  Identification of non-phosphate-containing small molecular weight inhibitors of the tyrosine kinase p56 Lck SH2 domain via in silico screening against the pY + 3 binding site. , 2004, Journal of medicinal chemistry.

[97]  A. Griffioen,et al.  Design of a Partial Peptide Mimetic of Anginex with Antiangiogenic and Anticancer Activity* , 2003, Journal of Biological Chemistry.

[98]  C. E. Peishoff,et al.  Conformations of Arg-Gly-Asp containing heterodetic cyclic peptides: solution and crystal studies , 1992 .

[99]  Dale L Boger,et al.  Solution-phase combinatorial libraries: modulating cellular signaling by targeting protein-protein or protein-DNA interactions. , 2003, Angewandte Chemie.

[100]  Michael Loran Dustin,et al.  The arrangement of the immunoglobulin-like domains of ICAM-1 and the binding sites for LFA-1 and rhinovirus , 1990, Cell.

[101]  J. Martin,et al.  Molecular recognition of macrocyclic peptidomimetic inhibitors by HIV-1 protease. , 1999, Biochemistry.

[102]  A. Hamilton,et al.  Terephthalamide derivatives as mimetics of the helical region of Bak peptide target Bcl-xL protein. , 2004, Bioorganic & medicinal chemistry letters.

[103]  Brian W. Metcalf,et al.  Inhibition of HIV-1 protease in infected T-lymphocytes by synthetic peptide analogues , 1990, Nature.

[104]  M. Zacharias,et al.  Accounting for global protein deformability during protein-protein and protein-ligand docking. , 2005, Biochimica et biophysica acta.

[105]  Yan-Li Song,et al.  Binding affinity difference induced by the stereochemistry of the sulfoxide bridge of the cyclic peptide inhibitors of Grb2-SH2 domain: NMR studies for the structural origin. , 2005, Biochemical and biophysical research communications.

[106]  Sibylle Ziegler,et al.  Noninvasive Imaging of αvβ3 Integrin Expression Using 18F-labeled RGD-containing Glycopeptide and Positron Emission Tomography , 2001 .

[107]  N. Yao,et al.  Potent 7-hydroxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid-based macrocyclic inhibitors of hepatitis C virus NS3 protease. , 2006, Journal of medicinal chemistry.

[108]  T. Burke,et al.  Macrocyclization in the design of a conformationally constrained Grb2 SH2 domain inhibitor. , 2001, Bioorganic & medicinal chemistry letters.

[109]  S. Willis,et al.  Life in the balance: how BH3-only proteins induce apoptosis. , 2005, Current opinion in cell biology.

[110]  J. Thornton,et al.  Diversity of protein–protein interactions , 2003, The EMBO journal.

[111]  Jorge Becerril,et al.  Design and application of an alpha-helix-mimetic scaffold based on an oligoamide-foldamer strategy: antagonism of the Bak BH3/Bcl-xL complex. , 2003, Angewandte Chemie.

[112]  Ziwei Huang,et al.  The chemical biology of apoptosis. Exploring protein-protein interactions and the life and death of cells with small molecules. , 2002, Chemistry & biology.

[113]  P. Furet,et al.  Discovery of potent antagonists of the interaction between human double minute 2 and tumor suppressor p53. , 2000, Journal of medicinal chemistry.

[114]  P. Toogood Inhibition of protein-protein association by small molecules: approaches and progress. , 2002, Journal of medicinal chemistry.

[115]  Steven Fletcher,et al.  Protein surface recognition and proteomimetics: mimics of protein surface structure and function. , 2005, Current opinion in chemical biology.

[116]  A. Hamilton,et al.  Toward proteomimetics: terphenyl derivatives as structural and functional mimics of extended regions of an alpha-helix. , 2001, Journal of the American Chemical Society.

[117]  S. Vasavanonda,et al.  ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[118]  J. Matthews,et al.  Protein-protein interactions in human disease. , 2005, Current opinion in structural biology.

[119]  Ho-il Choi,et al.  Synthesis of Irreversible HIV-1 Protease Inhibitors Containing Sulfonamide and Sulfone as Amide Bond Isosteres. , 1998 .

[120]  G. Rose,et al.  Hydrogen‐bonded turns in proteins: The case for a recount , 2005, Protein science : a publication of the Protein Society.

[121]  Andrew D. Hamilton,et al.  Terphenyl-Based Bak BH3 α-Helical Proteomimetics as Low-Molecular-Weight Antagonists of Bcl-xL , 2005 .

[122]  S. Agarwal,et al.  Design and modular parallel synthesis of a MCR derived alpha-helix mimetic protein-protein interaction inhibitor scaffold. , 2006, Bioorganic & medicinal chemistry letters.

[123]  A. Hamilton,et al.  Peptide and protein recognition by designed molecules. , 2000, Chemical reviews.

[124]  B. M. Jimenez,et al.  IBTM-Containing Gramicidin S Analogues: Evidence for IBTM as a Suitable Type II‘ β-Turn Mimetic1,2 , 1997 .

[125]  S. Bodary,et al.  Competition between intercellular adhesion molecule‐1 and a small‐molecule antagonist for a common binding site on the αl subunit of lymphocyte function‐associated antigen‐1 , 2006, Protein science : a publication of the Protein Society.

[126]  A. Otaka,et al.  Pharmacophore identification of a chemokine receptor (CXCR4) antagonist, T22 ([Tyr(5,12),Lys7]-polyphemusin II), which specifically blocks T cell-line-tropic HIV-1 infection. , 1998, Bioorganic & medicinal chemistry.

[127]  Harold P. Erickson,et al.  2.0 Å Crystal Structure of a Four-Domain Segment of Human Fibronectin Encompassing the RGD Loop and Synergy Region , 1996, Cell.

[128]  L. Presta,et al.  Identification of the binding site in intercellular adhesion molecule 1 for its receptor, leukocyte function-associated antigen 1. , 1997, Molecular biology of the cell.

[129]  Zhen-Dan Shi,et al.  Crystal structures of a high-affinity macrocyclic peptide mimetic in complex with the Grb2 SH2 domain. , 2005, Journal of molecular biology.

[130]  G. Rose,et al.  Turns in peptides and proteins. , 1985, Advances in protein chemistry.

[131]  D. Potenza,et al.  Potent integrin antagonists from a small library of RGD-including cyclic pseudopeptides. , 2001, Organic letters.

[132]  A. Hamilton,et al.  Strategies for targeting protein-protein interactions with synthetic agents. , 2005, Angewandte Chemie.

[133]  T. Hugli Protease inhibitors: novel therapeutic application and development. , 1996, Trends in biotechnology.

[134]  W. Delano Unraveling hot spots in binding interfaces: progress and challenges. , 2002, Current opinion in structural biology.

[135]  G. Milne,et al.  Potent inhibition of Grb2 SH2 domain binding by non-phosphate-containing ligands. , 1999, Journal of medicinal chemistry.

[136]  K. Burgess,et al.  Syntheses and Activities of New C10 β-Turn Peptidomimetics , 2004 .

[137]  A. Griffioen,et al.  Designed β-sheet peptides that inhibit proliferation and induce apoptosis in endothelial cells , 2004, Angiogenesis.

[138]  S. Korsmeyer,et al.  Activation of Apoptosis in Vivo by a Hydrocarbon-Stapled BH3 Helix , 2004, Science.

[139]  Oliver Zerbe,et al.  Structure–Activity Studies in a Family of β‐Hairpin Protein Epitope Mimetic Inhibitors of the p53–HDM2 Protein–Protein Interaction , 2006 .

[140]  M. Martín-Martínez,et al.  PACAP27 Analogues Incorporating Type II/II’ β-Turn Mimetics , 2001 .

[141]  Horst Kessler,et al.  Cyclic RGD Peptides Containing β-Turn Mimetics , 1996 .

[142]  E Ruoslahti,et al.  Solution structures and integrin binding activities of an RGD peptide with two isomers. , 2001, Biochemistry.

[143]  D. Rees,et al.  The synthesis of 1,6-disubstituted indanes which mimic the orientation of amino acid side-chains in a protein alpha-helix motif. , 1992 .

[144]  P. Arora,et al.  Enhanced metabolic stability and protein-binding properties of artificial alpha helices derived from a hydrogen-bond surrogate: application to Bcl-xL. , 2005, Angewandte Chemie.

[145]  A. Otaka,et al.  Downsizing of an HIV-cell fusion inhibitor, T22 ([Tyr5,12, Lys7]-polyphemusin II), with the maintenance of anti-HIV activity and solution structure. , 1998, Bioorganic & medicinal chemistry.

[146]  H. S. Struijker Boudier,et al.  Anginex, a designed peptide that inhibits angiogenesis. , 2001, The Biochemical journal.

[147]  Kristian Rother,et al.  Matching organic libraries with protein-substructures , 2001, J. Comput. Aided Mol. Des..

[148]  Thilo Stehle,et al.  Crystal Structure of the Extracellular Segment of Integrin αVβ3 in Complex with an Arg-Gly-Asp Ligand , 2002, Science.

[149]  Stephen Hanessian,et al.  Design and synthesis of conformationally constrained amino acids as versatile scaffolds and peptide mimetics , 1997 .

[150]  D. Fairlie,et al.  Beta-strand mimetics. , 2004, Chemical reviews.

[151]  K. Burgess,et al.  Long-Lasting Rescue of Age-Associated Deficits in Cognition and the CNS Cholinergic Phenotype by a Partial Agonist Peptidomimetic Ligand of TrkA , 2004, The Journal of Neuroscience.

[152]  K. Burgess,et al.  Ring closure to beta-turn mimics via copper-catalyzed azide/alkyne cycloadditions. , 2005, The Journal of organic chemistry.

[153]  Timothy A. Springer,et al.  Therapeutic antagonists and conformational regulation of integrin function , 2003, Nature Reviews Drug Discovery.

[154]  P. Lewi,et al.  Protein–protein interactions: mechanisms and modification by drugs , 2002, Journal of molecular recognition : JMR.

[155]  K. Gehring,et al.  Design and solution structure of functional peptide mimetics of nerve growth factor. , 2000, Journal of medicinal chemistry.

[156]  P. Furet,et al.  Structure-based design and synthesis of high affinity tripeptide ligands of the Grb2-SH2 domain. , 1998, Journal of medicinal chemistry.

[157]  W. Delano,et al.  Convergent solutions to binding at a protein-protein interface. , 2000, Science.

[158]  Giorgio Palù,et al.  Disruption of protein–protein interactions: Towards new targets for chemotherapy , 2005, Journal of cellular physiology.

[159]  Toshiaki Hara,et al.  Probing the structural requirements of peptoids that inhibit HDM2-p53 interactions. , 2006, Journal of the American Chemical Society.

[160]  J. Trent,et al.  Stereoselective synthesis of [L-Arg-L/D-3-(2-naphthyl)alanine]-type (E)-alkene dipeptide isosteres and its application to the synthesis and biological evaluation of pseudopeptide analogues of the CXCR4 antagonist FC131. , 2005, Journal of medicinal chemistry.

[161]  K. Gehring,et al.  Development of pharmacological agents for targeting neurotrophins and their receptors. , 2000, Trends in pharmacological sciences.

[162]  Thommey P. Thomas,et al.  Tumor angiogenic vasculature targeting with PAMAM dendrimer-RGD conjugates. , 2005, Chemical communications.

[163]  Vadim M Govorun,et al.  Protein‐protein interactions as a target for drugs in proteomics , 2003, Proteomics.

[164]  Stephen C Peiper,et al.  Identification of novel low molecular weight CXCR4 antagonists by structural tuning of cyclic tetrapeptide scaffolds. , 2005, Journal of medicinal chemistry.

[165]  M. Shimaoka,et al.  Intersubunit signal transmission in integrins by a receptor-like interaction with a pull spring. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[166]  D. Fairlie,et al.  Protease inhibitors: current status and future prospects. , 2000, Journal of medicinal chemistry.

[167]  W. Bode,et al.  A player of many parts: the spotlight falls on thrombin's structure. , 1993, Thrombosis research.

[168]  John A. Robinson,et al.  Structural Mimicry of Canonical Conformations in Antibody Hypervariable Loops Using Cyclic Peptides Containing a Heterochiral Diproline Template , 1999 .

[169]  Structure Activity Relationships , 2005 .

[170]  A. Griffioen,et al.  Beta-sheet is the bioactive conformation of the anti-angiogenic anginex peptide. , 2003, The Biochemical journal.

[171]  J. Nowick,et al.  Designed Molecules That Fold to Mimic Protein Secondary Structures , 2000 .

[172]  Lin Hong,et al.  Structure-based design of cycloamide–urethane-derived novel inhibitors of human brain memapsin 2 (β-secretase) , 2005 .

[173]  S. Sebti,et al.  Protein – Protein Interactions Terphenyl-Based Helical Mimetics That Disrupt the p 53 / HDM 2 Interaction * * , 2007 .

[174]  C. Dobson Protein Folding and Disease: a view from the first Horizon Symposium , 2003, Nature Reviews Drug Discovery.

[175]  K. Kitaura,et al.  Stereoselective synthesis of 3,6-disubstituted-3,6-dihydropyridin-2-ones as potential diketopiperazine mimetics using organocopper-mediated anti-SN2' reactions and their use in the preparation of low-molecule CXCR4 antagonists. , 2006, The Journal of organic chemistry.

[176]  K. Appelt,et al.  Isophthalic acid derivatives: amino acid surrogates for the inhibition of HIV-1 protease , 1995 .

[177]  R. Timpl,et al.  Arg‐Gly‐Asp constrained within cyclic pentapoptides Strong and selective inhibitors of cell adhesion to vitronectin and laminin fragment P1 , 1991, FEBS letters.

[178]  A. Otaka,et al.  Effective lowly cytotoxic analogs of an HIV-cell fusion inhibitor, T22 ([Tyr5,12, Lys7]-polyphemusin II). , 1998, Bioorganic & medicinal chemistry.

[179]  P. Chène Inhibiting the p53–MDM2 interaction: an important target for cancer therapy , 2003, Nature Reviews Cancer.

[180]  Mercedes Martín-Martínez,et al.  Conformationally constrained CCK4 analogues incorporating IBTM and BTD beta-turn mimetics. , 2005, Journal of medicinal chemistry.

[181]  C. Nguyên,et al.  Chemogenomics with peptide secondary structure mimetics. , 2003, Combinatorial chemistry & high throughput screening.

[182]  John A. Robinson,et al.  Protein ligand design: from phage display to synthetic protein epitope mimetics in human antibody Fc-binding peptidomimetics. , 2006, Journal of the American Chemical Society.

[183]  Jennifer L. Martin,et al.  Regioselective Structural and Functional Mimicry of Peptides - Design of Hydrolytically-Stable Cyclic Peptidomimetic Inhibitors of Hiv-1 Protease , 1995 .

[184]  T. Berg Modulation of protein-protein interactions with small organic molecules. , 2003, Angewandte Chemie.

[185]  Kazuya Machida,et al.  The SH2 domain: versatile signaling module and pharmaceutical target. , 2005, Biochimica et biophysica acta.

[186]  A. Cochran,et al.  Protein-protein interfaces: mimics and inhibitors. , 2001, Current opinion in chemical biology.

[187]  R. Linhardt,et al.  Interaction of Secretory Leukocyte Protease Inhibitor with Heparin Inhibits Proteases Involved in Asthma* , 1998, The Journal of Biological Chemistry.

[188]  Andrew D. Hamilton,et al.  Synthesis of a 2,3‘;6‘,3‘ ‘-Terpyridine Scaffold as an α-Helix Mimetic , 2005 .

[189]  Yoshua Bengio,et al.  Selective small molecule peptidomimetic ligands of TrkC and TrkA receptors afford discrete or complete neurotrophic activities. , 2005, Chemistry & biology.

[190]  Dajun Yang,et al.  Development of a phosphatase-stable phosphotyrosyl mimetic suitably protected for the synthesis of high-affinity Grb2 SH2 domain-binding ligands. , 2002, Bioorganic & medicinal chemistry letters.

[191]  Richard S Larson,et al.  Design and structure of peptide and peptidomimetic antagonists of protein-protein interaction. , 2005, Current protein & peptide science.

[192]  T. Aoki,et al.  Design, synthesis, and structure-activity relationships of potent GPIIb/IIIa antagonists: discovery of FK419. , 2005, Bioorganic & medicinal chemistry.

[193]  John A. Robinson,et al.  Exploiting Conformationally Constrained Peptidomimetics and an Efficient Human‐Compatible Delivery System in Synthetic Vaccine Design , 2001, Chembiochem : a European journal of chemical biology.

[194]  J. Clemente,et al.  Macrocyclic inhibitors of the malarial aspartic proteases plasmepsin I, II, and IV. , 2006, Bioorganic & medicinal chemistry.

[195]  R. Hughes,et al.  Design of Potent Peptide Mimetics of Brain-derived Neurotrophic Factor* , 2003, Journal of Biological Chemistry.

[196]  V. Chow,et al.  Design, structure and biological activity of beta-turn peptides of CD2 protein for inhibition of T-cell adhesion. , 2004, European journal of biochemistry.

[197]  Michelle Arkin,et al.  Protein-protein interactions and cancer: small molecules going in for the kill. , 2005, Current opinion in chemical biology.

[198]  D. Roberts,et al.  Novel integrin antagonists derived from thrombospondins. , 2005, Current pharmaceutical design.

[199]  Structure-activity relationships for macrocyclic peptidomimetic inhibitors of HIV-1 protease , 1996 .

[200]  Helen E Blackwell,et al.  Highly Efficient Synthesis of Covalently Cross-Linked Peptide Helices by Ring-Closing Metathesis. , 1998, Angewandte Chemie.

[201]  D. Fowlkes,et al.  Peptide antagonists of the human estrogen receptor. , 1999, Science.

[202]  C. E. Peishoff,et al.  Discovery of Potent Nonpeptide Vitronectin Receptor (αVβ3) Antagonists , 1997 .

[203]  Stephen Hanessian,et al.  Structure-based design, synthesis, and memapsin 2 (BACE) inhibitory activity of carbocyclic and heterocyclic peptidomimetics. , 2005, Journal of medicinal chemistry.

[204]  D. Fairlie,et al.  Synthesis, stability, antiviral activity, and protease-bound structures of substrate-mimicking constrained macrocyclic inhibitors of HIV-1 protease. , 2000, Journal of medicinal chemistry.

[205]  John A. Robinson,et al.  Crystal structure of an NPNA-repeat motif from the circumsporozoite protein of the malaria parasite Plasmodium falciparum. , 2006, Chemical communications.

[206]  Andrew D. Hamilton,et al.  Development of a Potent Bcl-xL Antagonist Based on α-Helix Mimicry , 2002 .

[207]  Jiandong Chen,et al.  p53 α-Helix mimetics antagonize p53/MDM2 interaction and activate p53 , 2005, Molecular Cancer Therapeutics.

[208]  Ronald Kühne,et al.  Recognition of proline-rich motifs by protein-protein-interaction domains. , 2005, Angewandte Chemie.

[209]  Dajun Yang,et al.  Macrocyclization in the design of Grb2 SH2 domain-binding ligands exhibiting high potency in whole-cell systems. , 2003, Journal of medicinal chemistry.

[210]  Teppei Ogawa,et al.  Structure-activity relationship studies on CXCR4 antagonists having cyclic pentapeptide scaffolds. , 2005, Organic & biomolecular chemistry.